Nevro (NVRO) Set to Announce Earnings on Tuesday

Nevro (NYSE:NVRO) will post its quarterly earnings results after the market closes on Tuesday, August 6th. Analysts expect Nevro to post earnings of ($0.63) per share for the quarter. Persons interested in listening to the company’s earnings conference call can do so using this link.

Nevro (NYSE:NVRO) last announced its earnings results on Tuesday, May 7th. The medical equipment provider reported ($0.70) EPS for the quarter, topping the consensus estimate of ($1.02) by $0.32. Nevro had a negative return on equity of 27.48% and a negative net margin of 19.17%. The firm had revenue of $101.90 million for the quarter, compared to analysts’ expectations of $97.90 million. During the same quarter in the previous year, the company earned ($0.98) earnings per share. The firm’s quarterly revenue was up 5.8% compared to the same quarter last year. On average, analysts expect Nevro to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Nevro Price Performance

Shares of NYSE:NVRO opened at $9.05 on Monday. Nevro has a 12 month low of $7.46 and a 12 month high of $22.64. The stock has a market cap of $332.41 million, a price-to-earnings ratio of -3.95 and a beta of 0.91. The stock’s 50 day moving average price is $9.07 and its 200 day moving average price is $12.29. The company has a debt-to-equity ratio of 0.77, a current ratio of 7.38 and a quick ratio of 5.57.

Wall Street Analyst Weigh In

Several brokerages recently commented on NVRO. Canaccord Genuity Group dropped their target price on Nevro from $17.00 to $11.00 and set a “hold” rating on the stock in a report on Wednesday, May 8th. Mizuho dropped their target price on Nevro from $20.00 to $16.00 and set a “neutral” rating on the stock in a report on Thursday, April 11th. Wells Fargo & Company dropped their target price on Nevro from $14.00 to $13.00 and set an “equal weight” rating on the stock in a report on Wednesday, May 8th. Truist Financial dropped their price target on Nevro from $11.00 to $10.00 and set a “hold” rating on the stock in a report on Tuesday, July 16th. Finally, Royal Bank of Canada dropped their price target on Nevro from $18.00 to $16.00 and set a “sector perform” rating on the stock in a report on Monday, April 15th. Two research analysts have rated the stock with a sell rating and eleven have given a hold rating to the company’s stock. Based on data from MarketBeat, Nevro has a consensus rating of “Hold” and a consensus price target of $14.11.

Nevro Company Profile

Nevro Corp., a medical device company, engages in the provision of products for patients suffering from chronic pain in the United States and internationally. The company provides HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS implantable pulse generator (IPG) system, an evidence-based neuromodulation system for the treatment of chronic back and leg pain through paresthesia-free 10 kHz therapy, as well as offers Senza II and Senza Omnia SCS IPG systems.